TrialCancer discovery2023

Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.

Takafumi Koyama et al.PubMed ↗Publisher ↗

No numbers read from the abstract.